Published in Ann Oncol on July 13, 2007
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Aging, cancer, and cancer vaccines. Immun Ageing (2012) 0.98
Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol (2014) 0.95
Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst (2014) 0.83
Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med (2015) 0.82
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. J Clin Oncol (2016) 0.79
High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplant (2015) 0.78
Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med (2015) 0.78
Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol (2015) 0.78
Renal insufficiency and cancer treatments. ESMO Open (2016) 0.77
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. Cancer Med (2015) 0.77
Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center. Einstein (Sao Paulo) (2014) 0.77
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer (2014) 0.77
Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer. J Cancer Res Clin Oncol (2013) 0.76
Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with 99mTc-DTPA and by using Serum Creatinine based Formulae: A Prospective Study. J Clin Diagn Res (2016) 0.75
Association between renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol (2016) 0.75
The Effects of Advanced Age and Serum α1 -Acid Glycoprotein on Docetaxel Unbound Exposure and Dose-limiting Toxicity in Cancer Patients. Br J Clin Pharmacol (2017) 0.75
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol (2007) 1.98
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol (2007) 1.98
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ (1989) 1.96
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer (1997) 1.84
EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer (2010) 1.80
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol (2006) 1.53
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer (2003) 1.48
The early stool patterns of young children with autistic spectrum disorder. Arch Dis Child (2009) 1.45
Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract (2003) 1.41
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol (2005) 1.33
Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods (2007) 1.29
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol (2008) 1.29
Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr (1990) 1.21
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer (1995) 1.20
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res (1989) 1.19
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol (2005) 1.19
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med (1995) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst (1993) 1.14
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 1.13
Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer (1997) 1.13
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol (2009) 1.12
Chemotherapy in elderly patients with colorectal cancer. Ann Oncol (2001) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol (2013) 1.10
Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol (1997) 1.10
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer (1999) 1.09
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol (2011) 1.07
Conception rates and in-vitro fertilisation. Lancet (1990) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Different outcome variables yield different results! Ann Oncol (2012) 1.06
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol (1998) 1.04
Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol (2009) 1.04
Cancer and renal insufficiency results of the BIRMA study. Br J Cancer (2010) 1.03
Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. BJU Int (2012) 1.00
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol (2004) 1.00
Clinical pharmacology of cancer therapies in older adults. Br J Cancer (2008) 1.00
Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther (2000) 0.98
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol (2012) 0.97
Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood (1996) 0.97
Triple-negative breast cancer in the older population. Ann Oncol (2012) 0.96
International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer (2007) 0.96
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer (1998) 0.95
The treatment of early breast cancer in women over the age of 70. Br J Cancer (2011) 0.95
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res (1994) 0.95
Commission of the European Communities "Europe Against Cancer" Programme. European school of oncology advisory report. Cancer treatment in the elderly. Eur J Cancer (1993) 0.95
Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer (2007) 0.94
Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest (1996) 0.94
Assessment of the older cancer patient. Hematol Oncol Clin North Am (2000) 0.94
Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer (2010) 0.92
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer (2014) 0.92
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol (2005) 0.90
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Res Treat (2010) 0.90
New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer (2000) 0.89
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos (1998) 0.89
Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol (1998) 0.89
Phase II study of tauromustine in malignant glioma. Eur J Cancer (1992) 0.88
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol (1993) 0.88
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann Oncol (2011) 0.88
Clinical research in the older cancer patient. Hematol Oncol Clin North Am (2000) 0.87
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol (2011) 0.87
Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. Ann Oncol (2013) 0.86
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma (2006) 0.86
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer (2005) 0.85
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol (1995) 0.85
IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing. Autoimmunity (1994) 0.85
Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol (1993) 0.85
Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer (1995) 0.85
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol (2011) 0.85
Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology (2011) 0.84
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol (2006) 0.84
Ovarian cyst aspiration and the outcome of in vitro fertilization. Fertil Steril (1990) 0.84
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer (2004) 0.84
Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen. Am J Hematol (1999) 0.83
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol (1999) 0.83
Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J (2003) 0.83
Adjuvant chemotherapy in the elderly. Ann Oncol (2003) 0.83
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol (2012) 0.83
Elective surgery for gastrointestinal tumours in the elderly. Ann Oncol (1997) 0.82
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer (1998) 0.82
An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients. Cancer Chemother Pharmacol (1986) 0.82
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol (1991) 0.82
Anthracycline analysis by capillary electrophoresis. Application to the analysis of daunorubicine in Kaposi sarcoma tumor. J Chromatogr A (1999) 0.82
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat (2014) 0.81
Optimal selection of antiemetics in children receiving cancer chemotherapy. Support Care Cancer (1998) 0.81
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res (2001) 0.81
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Res Treat (2007) 0.81
The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Breast (2013) 0.81
Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Res Treat (2011) 0.81